Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure–safety relationships

Publisher: John Wiley & Sons Inc

E-ISSN: 1552-4604|55|3|336-347

ISSN: 0091-2700

Source: JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.3, 2015-03, pp. : 336-347

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content